These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20413453)

  • 1. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
    Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
    J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
    Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
    Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
    Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
    Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
    Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
    Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
    Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
    Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA
    Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren: clinical experience and future perspectives of renin inhibition.
    Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
    Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
    Chung JH; Choi DH; Choi JS
    Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.
    Tsukimoto M; Ohashi R; Torimoto N; Togo Y; Suzuki T; Maeda T; Kagawa Y
    Biopharm Drug Dispos; 2015 Jan; 36(1):15-33. PubMed ID: 25264342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.